MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze EXEL →
    • FindStock Picks / Stock Screener
    • Value · EXELIntrinsic Value Calculator
    • Invest · EXELInvestment Case
    • Hold · EXEL5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
EXEL stock logo

EXEL

Exelixis, Inc.

$64.63
-1.2
 (-1.82%)
Exchange:  NASDAQ
Market Cap:  16.245B
Shares Outstanding:  271.567M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Michael Morrissey
Full Time Employees:  1077
Address: 
1851 Harbor Bay Parkway
Alameda
CA
94502
US
Website:  https://www.exelixis.com
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company’s developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin’s lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

EXEL full analysis

04/07/2025

Welcome to MARKETSNAP’s SWOT analysis for Exelixis! If you’re a long-term investor looking to build wealth and dig into some promising biotech opportunities, you’re in the right place. Today, we’re breaking down Exelixis, a company that’s been making waves in the oncology space. Let’s dive into who they are, what’s been happening with them lately, and then get into the meat of our SWOT analysis to see if this stock deserves a spot in your portfolio. First off, for those…

Open MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
EXEXEL logoEXELExelixis, Inc.16.2B18.721.739.7%
ASASND logoASNDAscendis Pharma A/S16.6B16.215.411.4%
NBNBIX logoNBIXNeurocrine Biosciences, Inc.15.2B21.620.514.3%
BBBBIO logoBBIOBridgeBio Pharma, Inc.14.8B——-23.6%
JAJAZZ logoJAZZJazz Pharmaceuticals plc14.8B64.315.47.2%
ALALNY logoALNYAlnylam Pharmaceuticals, Inc.19.3B7.17.115.4%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/10/29 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,830,2082,168,7012,320,126
Gross Profit1,757,6612,092,4852,236,429
EBITDA283,238718,752921,756
Operating Income170,885604,617872,191
Net Income207,765521,267782,570

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,942,3572,947,6902,844,423
Total Liabilities678,445703,487683,104
Total Stockholders Equity2,263,9122,244,2032,161,319
Total Debt189,944190,823173,038
Cash and Cash Equivalents262,994217,374482,488

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow333,324699,971884,267
Capital Expenditure-162,969-66,185-39,928
Free Cash Flow170,355633,786844,339
Net Income207,765521,267782,570
Net Change in Cash-239,683-45,620265,114

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2031Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)3,231,444.535Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)3,636,255.495Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)3,476,989.856Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)2,047,019.149Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)2,366,869.833Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)2,241,028.806Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)1,522,471.725Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)1,776,196.342Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)1,676,371.742Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)848,195.769Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)954,451.328Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)912,646.977Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)5.950Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)6.300Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)5.400Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)5Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)3Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
2.169B  ?P/S
 (TTM)
: 
6.51
?Net Income
 (TTM)
: 
521.267M  ?P/E
 (TTM)
: 
18.73
?Enterprise Value
 (TTM)
: 
16.103B  ?EV/FCF
 (TTM)
: 
13.98
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
45.54%  ?ROIC
 (TTM)
: 
39.65%
?Net Debt
 (TTM)
: 
-895.442M  ?Debt/Equity
 (TTM)
: 
0.09
?P/B
 (TTM)
: 
8.7  ?Current Ratio
 (TTM)
: 
3.21

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
21.69Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Strong Revenue Performance: EXEL has demonstrated consistent revenue growth as reported in recent income statements, reflecting robust demand for its products or services within the industry. This aligns with positive industry trends indicated by sector performance metrics.
  • Healthy Cash Flow: The cash flow statements highlight strong net cash provided by operating activities and positive free cash flow, indicating operational efficiency and the ability to fund growth initiatives or return value to shareholders.
  • Solid Balance Sheet: Balance sheet data shows a favorable current ratio and manageable debt-to-equity ratio, suggesting financial stability and the capacity to weather economic downturns compared to industry averages.
  • Positive Earnings Call Insights: The latest earnings call transcript reflects management’s confidence in sustained growth, with key financial results meeting or exceeding expectations, reinforcing investor trust in strategic execution.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates EXEL intrinsic value between $82.20 – $94.28 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate EXEL Intrinsic Value

Common questions about EXEL valuation

Is Exelixis, Inc. (EXEL) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Exelixis, Inc. (EXEL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is EXEL a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether EXEL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is EXEL’s P/E ratio?

You can see EXEL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for EXEL?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is EXEL a good long-term investment?

Whether EXEL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Exelixis, Inc.

  • Exelixis, Inc. intrinsic value calculatorEstimate what the business is worth
  • Exelixis, Inc. 5-year outlookWhat has to go right, and what could go wrong
EXEL

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-1.82
MarketSnap

Trading Metrics:

Open: 65.9   Previous Close: 65.83
Day Low: 64.44   Day High: 66.94
Year Low: 39.71   Year High: 73.69
Price Avg 50: 63.03   Price Avg 200: 52.75
Volume: 2.194M   Average Volume: 2.481M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

74,363 Shares of Exelixis, Inc. $EXEL Purchased by Edgestream Partners L.P.
20-11-2026 04:46
74,363 Shares of Exelixis, Inc. $EXEL Purchased by Edgestream Partners L.P.
Exelixis Eyes Q1 Zanza Data as It Plans Beyond CABO
18-11-2026 22:12
Exelixis Eyes Q1 Zanza Data as It Plans Beyond CABO
Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything
16-11-2026 16:32
Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything
Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib
11-11-2026 17:12
Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib
Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
10-11-2026 13:20
Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
02-11-2026 10:16
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze EXEL →
    • FindStock Picks / Stock Screener
    • Value · EXELIntrinsic Value Calculator
    • Invest · EXELInvestment Case
    • Hold · EXEL5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.